about
Validation of functional imaging as a biomarker for radiation treatment responseParticle therapy for non-small cell lung tumors: where do we stand? A systematic review of the literatureImaging-Based Treatment Adaptation in Radiation OncologyCorrelation between tumor oxygenation and 18F-fluoromisonidazole PET data simulated based on microvessel images.[Melanoma brain metastases : Treatment options].PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.Patient selection for whole brain radiotherapy (WBRT) in a large lung cancer cohort: Impact of a new Dutch guideline on brain metastases.Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging.Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer.The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis.Locally advanced verrucous carcinoma of the oral cavity: treatment using customized mold HDR brachytherapy instead of hemi-maxillectomy.Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives.A qualitative synthesis of the evidence behind elective lymph node irradiation in oesophageal cancer.Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake.Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients.'Rapid Learning health care in oncology' - an approach towards decision support systems enabling customised radiotherapy'.Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription.FMISO as a Biomarker for Clinical Radiation Oncology.Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer - A survival model with external validation.Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study.Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia--a simulation study.Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy.Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome.Modelling and simulation of [18F]fluoromisonidazole dynamics based on histology-derived microvessel maps."Combined 18F-FDG-PET/CT imaging in radiotherapy target delineation for head-and-neck cancer": in regard to Guido et al. (Int J Radiat Oncol Biol Phys 2009;73:759-763).18F-FDG and 18F-FLT do not discriminate between reactive and metastatic lymph nodes in oral cancer.3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients.Is integrated transit planar portal dosimetry able to detect geometric changes in lung cancer patients treated with volumetric modulated arc therapy?In response to "histopathologic validation of 3'-deoxy-3'-(18)F-fluorothymidine PET for detecting tumour repopulation during fractionated radiotherapy in human FaDu squamous cell carcinoma in nude mice".First clinical results of adaptive radiotherapy based on 3D portal dosimetry for lung cancer patients with atelectasis treated with volumetric-modulated arc therapy (VMAT).Definitive radiation therapy for treatment of laryngeal carcinoma: impact of local relapse on outcome and implications for treatment strategies.Multivariable normal-tissue complication modeling of acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy.Evaluating the use of optimally respiratory gated 18F-FDG-PET in target volume delineation and its influence on radiation doses to the organs at risk in non-small-cell lung cancer patients.18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome.A teaching intervention in a contouring dummy run improved target volume delineation in locally advanced non-small cell lung cancer: Reducing the interobserver variability in multicentre clinical studies.Modelling and simulation of the influence of acute and chronic hypoxia on [18F]fluoromisonidazole PET imaging.18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.18F-FLT PET changes during radio - therapy combined with cetuximab in head and neck squamous cell carcinoma patients
P50
Q26823165-CF8DCDB1-2BEE-481F-9765-768EAFD8BC1DQ27023426-6162BCC2-F35C-4209-839A-6D5DD24AD2D4Q28088626-364D1302-0DA3-45ED-883F-A9C9A6C1B91EQ30663793-AB4EB941-996C-460A-9EBE-959E9E404242Q31098294-2B05F169-B4CD-4726-A252-9CB4B7A8DE0CQ33606680-B009B0E5-EC72-4AE2-B8FD-A52C7CA3EB46Q35154586-D4CB8434-4E13-44AE-ABAA-B291F0F0300AQ35546673-40F1CF0A-1984-4727-9FD8-7BBC99B38072Q35731341-C59D810F-4A4E-4922-BD4F-71F83A177CC3Q35916957-9093211E-6226-41F7-B356-0E622417C0F7Q38130430-5BB15C64-985B-40C8-A287-EA2165E34E94Q38245374-65CFAB6A-4F96-45A2-8A53-FF0D4DA44BF4Q38281397-560A03EC-6FF9-4AB7-8862-6E6437F5749AQ38413065-D0224C19-32BA-4E84-9622-64005F3FC82AQ38444389-6AC8236D-0649-4D07-AE87-77FBAF099E54Q38445435-976AC778-C2BB-4362-8B1D-E0A7B7F1DBA3Q38609742-7304C309-3951-441D-BA9C-7A1F583E7537Q38869449-AC5AD821-3C27-43AC-8BFD-14D6EC5960EEQ38924078-00197BB0-7B96-4865-937F-F836A7CB4B8DQ39800444-FE594BEC-BE22-422C-91B4-BB2DE18BDE45Q40590117-487F2833-24A5-45C8-B1A7-CEA2AE9BC007Q40704400-51329C17-6CB0-4159-950F-800F9839AEE0Q40919306-5BE6416C-61B6-481B-8CAD-AFCB097E0FE4Q43491287-F302EEE9-5C01-4199-95F7-639DE86FD7ADQ45087708-D97E81FE-39C1-45EF-8704-E633D37DB5BDQ45974384-017809BB-E544-48DF-87C7-0784089C2751Q46119190-7ADC9A30-471F-4734-98EE-06438E03E93FQ48331179-AB80A033-5EA7-4606-BD5F-9EC004EAF8FCQ50577551-88B0845F-BB7D-4CAD-803B-25B605E008FAQ50615267-401829DD-B053-42A7-8FC5-1C3BA7D8B986Q50724395-C508FF0C-F22A-4B6D-A295-63E112BBDBDBQ50725942-9D1AE325-FD5C-44A8-ADA8-EE5EC1FA6821Q50988027-99674660-E19B-4E69-9FFF-6E4D228D0CEBQ51586605-854725C3-40EC-4019-90BB-F9717A5B6493Q53123607-F403D9AA-5717-4290-ADBC-6D29CF3EC35EQ53165187-6430A3C6-5574-477A-8A12-357D042D7155Q53172133-B6EDA309-AD9A-43F8-AC9F-C3A76975FCCAQ53483877-3813DA72-23AB-41AB-8EF5-EEE5DB3B5803Q55469635-4A92B14F-1753-4F97-9F11-0EC3268436A0Q57779467-05AA427B-B84A-4E08-AC4E-DF3E44D7DBD4
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Esther G Troost
@nl
Esther G Troost
@sl
Esther G. Troost
@en
Esther G. Troost
@es
type
label
Esther G Troost
@nl
Esther G Troost
@sl
Esther G. Troost
@en
Esther G. Troost
@es
prefLabel
Esther G Troost
@nl
Esther G Troost
@sl
Esther G. Troost
@en
Esther G. Troost
@es
P106
P1153
9737939700
P21
P31
P496
0000-0001-9550-9050